Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe (OTC:MEHCQ) after a ...

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

DNA data saved: 23andMe co-founder Anne Wojcicki has bid $305 million through a nonprofit to acquire her bankrupt company, ...

Anne Wojcicki's winning bid to reclaim control of 23andMe doesn't necessarily end the fight over what happens to the DNA of 15 million people collected by the bankrupt consumer genomics company.

23andMe's co-founder and former chief executive, Anne Wojcicki, looks set to regain control of the business after emerging ...

23andMe struck a deal last month with Regeneron Pharmaceuticals Inc., but Wojcicki complained about the bidding process, ...

Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of the DNA-testing company she co-founded.

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

A cyber attack on the genetic testing firm saw personal information of 155,592 UK residents accessed in a major cyber attack in 2023.

Anne Wojcicki’s winning bid to reclaim control of 23andMe doesn’t necessarily end the fight over what happens to the DNA of ...